Patient disposition
death
DISEASE PROGRESSION
Overall, 726 postmenopausal women were randomly assigned between June 18, 2015, and June 10, 2016: 484 to the ribociclib arm and 242 to the placebo arm. The baseline characteristics of the patients were included in the previously published analyses [In the first-line (de novo or late relapse) subgroup, 237 patients were randomized to the ribociclib arm and 128 to the placebo arm. A total of 39 of 237 patients (16.5%) in the ribociclib arm and 11 of 128 patients (8.6%) in the placebo arm were still receiving study treatment at the cutoff date. Following the final OS analysis, 2 patients (1.6%) in the placebo arm elected to cross over and received at least one dose of ribociclib. A total of 133 patients (56.1%) in the ribociclib arm and 101 patients (78.9%) in the placebo arm discontinued first-line treatment due to disease progression. AEs (7.7%), patient/guardian decisions (7.1%), physician decision (6.8%), death (0.3%), and protocol deviation (0.3%) were other reasons for discontinuing first-line treatment (Additional file 